Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Accumulated Expenses: 2023-2024

Historic Accumulated Expenses for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to $29.9 million.

  • Inhibrx Biosciences' Accumulated Expenses fell 9.79% to $27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.0 million, marking a year-over-year decrease of 9.79%. This contributed to the annual value of $29.9 million for FY2024, which is 30.96% down from last year.
  • Per Inhibrx Biosciences' latest filing, its Accumulated Expenses stood at $29.9 million for FY2024, which was down 30.96% from $43.3 million recorded in FY2023.
  • In the past 5 years, Inhibrx Biosciences' Accumulated Expenses ranged from a high of $43.3 million in FY2023 and a low of $29.9 million during FY2024.
  • In the last 2 years, Inhibrx Biosciences' Accumulated Expenses had a median value of $36.6 million in 2023 and averaged $36.6 million.
  • Data for Inhibrx Biosciences' Accumulated Expenses shows a maximum YoY slumped of 30.96% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Inhibrx Biosciences' Accumulated Expenses stood at $43.3 million in 2023, then plummeted by 30.96% to $29.9 million in 2024.